Hostname: page-component-586b7cd67f-rcrh6 Total loading time: 0 Render date: 2024-11-22T07:42:38.910Z Has data issue: false hasContentIssue false
  • English
  • Français

Evidence-Based Pharmacotherapy for Mood and Anxiety Disorders with Concurrent Alcoholism

Published online by Cambridge University Press:  07 November 2014

Kathleen T. Brady
Get access Rights & Permissions [Opens in a new window]

Abstract

Co-occurring psychiatric and alcohol use disorders can have devastating personal and societal effects, yet little evidence exists to guide clinical treatment. In the face of scant data, individual practitioners must rely instead on professional experience and those limited practice guidelines that currently exist. The American Psychiatric Association (APA) advises that failure to treat a concurrent psychiatric disorder reduces the likelihood that the treatment for a substance use disorder (SUD) will be effective. Indeed, the effects of nontreatment were demonstrated in a prospective study assessing alcohol-dependent patients for 1 year following hospitalization for alcohol dependence, in which untreated depression was directly associated with a shorter time to first drink. The results also showed that among those patients with depression (Slide 1), taking antidepressants at the time of discharge increased the likelihood of an individual remaining abstinent during the follow-up period.

Type
Expert Roundtable Supplement
Information
CNS Spectrums , Volume 13 , Issue S6: Bridging the Clinical Gap: Managing Patients with Co-occurring Mood, Anxiety, and Alcohol Use Disorders , April 2008 , pp. 7 - 9
Copyright
Copyright © Cambridge University Press 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.American Psychiatric Association. Practice Guideline for the Treatment of Patients with Substance Use Disorders. 2nd Edition. New York, NY: American Psychiatric Association; 2006.Google Scholar
2.Greenfield, SF, Weiss, RD, Muenz, LR, et al. The effect of depression on return to drinking. Arch Gen Psychiatry. 1998;55(3):259–265.CrossRefGoogle ScholarPubMed
3.Substance Abuse and Mental Health Services Administration, United States Department of Health and Human Services. Treatment Improvement Protocols (TIP) 9: Assessment and treatment of patients with coexisting mental illness and alcohol and other drug abuse. Rockville, MD; 2002.Google Scholar
4.O'Brien, CP, Charney, DS, Lewis, L, et al. Priority actions to improve the care of persons with co-occurring substance abuse and other mental disorders: a call to action. Biol Psychiatry. 2004;56(10):703–713.CrossRefGoogle ScholarPubMed
5.Nunes, EV, Levin, FR.Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis. JAMA. 2004;291(15):1887–1896.CrossRefGoogle ScholarPubMed
6.Altamura, AC, Mauri, MC, Girardi, T, Panetta, B.Alcoholism and depression: a placebo controlled study with viloxazine. Int J Clin Pharmacol Res. 1990;10(5):293–298.Google ScholarPubMed
7.Roy, A.Placebo-controlled study of sertraline in depressed recently abstinent alcoholics. Biol Psychiatry. 1998;44(7):633–637.Google Scholar
8.Mason, BJ, Kocsis, JH, Ritvo, EC, Cutler, RB.A double-blind, placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression. JAMA. 1996;275(10):761–767.CrossRefGoogle ScholarPubMed
9.Nunes, EV, Quitkin, FM, Donovan, SJ, et al. Imipramine treatment of opiate-dependent patients with depressive disorders. A placebo-controlled trial. Arch Gen Psychiatry. 1998;55(2):153–160.CrossRefGoogle ScholarPubMed
10.Nunes, EV, McGrath, PJ, Quitkin, FM, et al. Imipramine treatment of cocaine abuse: possible boundaries of efficacy. Drug Alcohol Depend. 1995;39(3):185–195.Google Scholar
11.Cornelius, JR, Salloum, IM, Ehler, JG, et al. Fluoxetine in depressed alcoholics. A double-blind, placebo-controlled trial. Arch Gen Psychiatry. 1997;54(8):700–705.CrossRefGoogle ScholarPubMed
12.McGrath, PJ, Nunes, EV, Stewart, JW, et al. Imipramine treatment of alcoholics with primary depression: A placebo-controlled clinical trial. Arch Gen Psychiatry. 1996;53(3):232–240.Google Scholar
13.Roy-Byrne, PP, Pages, KP, Russo, JE, et al. Nefazodone treatment of major depression in alcohol-dependent patients: a double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2000;20(2):129–136.Google Scholar
14.Moak, DH, Anton, RF, Latham, PK, Voronin, KE, Waid, RL, Durazo-Arvizu, R.Sertraline and cognitive behavioral therapy for depressed alcoholics: results of a placebo-controlled trial. J Clin Psychopharmacol. 2003;23(6):553–562.CrossRefGoogle ScholarPubMed
15.Carpenter, KM, Brooks, AC, Vosburg, SK, Nunes, EV.The effect of sertraline and environmental context on treating depression and illicit substance use among methadone maintained opiate dependent patients: a controlled clinical trial. Drug Alcohol Depend. 2004;74(2):123–134.Google Scholar
16.Schmitz, JM, Averill, P, Stotts, AL, Moeller, FG, Rhoades, HM, Grabowski, J.Fluoxetine treatment of cocaine-dependent patients with major depressive disorder. Drug Alcohol Depend. 2001;63(3):207–214.Google Scholar
17.Kleber, HD, Weissman, MM, Rounsaville, BJ, Wilber, CH, Prusoff, BA, Riordan, CE.Imipramine as treatment for depression in addicts. Arch Gen Psychiatry. 1983;40(6):649–653.Google Scholar
18.Petrakis, I, Carroll, KM, Nich, C, Gordon, L, Kosten, T, Rounsaville, B.Fluoxetine treatment of depressive disorders in methadone-maintained opiate addicts. Drug Alcohol Depend. 1998;50(3):221–226.Google Scholar
19.Pettinati, HM, Volpicelli, JR, Luck, G, Kranzler, HR, Rukstalis, MR, Cnaan, A.Double-blind clinical trial of sertraline treatment for alcohol dependence. J Clin Psychopharmacol. 2001;21(2):143–153.Google Scholar
20.Salloum, IM, Cornelius, JR, Daley, DC, Kirisci, L, Himmelhoch, JM, Thase, ME.Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study. Arch Gen Psychiatry. 2005;62(1):37–45.Google Scholar
21.Goldstein, BI, Diamantouros, A, Schaffer, A, Naranjo, CA.Pharmacotherapy of alcoholism in patients with co-morbid psychiatric disorders. Drugs. 2006:66(9):1229–1237.CrossRefGoogle ScholarPubMed
22.Lydiard, RB, Brawman-Mintzer, O, Ballenger, JC.Recent developments in the psychopharmacolo y of anxiety disorders. J Consult Clin Psychol. 1996;64(4):660–668.Google Scholar
23.Randall, CL, Johnson, MR, Thevos, AK, et al. Paroxetine for social anxiety and alcohol use in dual-diagnosed patients. Depress Anxiety. 2001;14(4):255–262.CrossRefGoogle ScholarPubMed
24.Pande, AC, Davidson, JR, Jefferson, JW, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol. 1999;19(4):341–348.Google Scholar
25.Brady, K, Pearlstein, T, Asnis, GM, et al. Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. JAMA. 2000;283(14):1837–1844.CrossRefGoogle ScholarPubMed
26.Marshall, RD, Beebe, KL, Oldham, M, Zaninelli, R.Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study. Am J Psychiatry. 2001;158(12):1982–1988.CrossRefGoogle ScholarPubMed
27.Davidson, JR, Rothbaum, BO, van der Kolk, BA, Sikes, CR, Farfel, GM.Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Arch Gen Psychiatry. 2001;58(5):485–492.CrossRefGoogle ScholarPubMed
28.Brady, KT, Sonne, S, Anton, RF, Randall, CL, Back, SE, Simpson, K.Sertraline in the treatment of co-occurring alcohol dependence and posttraumatic stress disorder. Alcohol Clin Exp Res. 2005;29(3):395–401.Google Scholar
29.Physicians Desk Reference 2006: Guide to Drug Interactions, Side Effects, and Indications. 60th ed. Montvale, NJ: Thomson PDR; 2006:1175–3419.Google Scholar
30.Brown, ES, Beard, L, Dobbs, L, Rush, AJ.Naltrexone in patients with bipolar disorder and alcohol dependence. Depress Anxiety. 2006;23(8):492–495.Google Scholar
31.Larson, EW, Olincy, A, Rummans, TA, Morse, RM.Disulfiram treatment of patients with both alcohol dependence and other psychiatric disorders: a review. Alcohol Clin Exp Res. 1992;16(1):125–130.CrossRefGoogle ScholarPubMed
32.Kofoed, L, Kania, J, Walsh, T, Atkinson, RM.Outpatient treatment of patients with substance abuse and coexisting psychiatric disorders. Am J Psychiatry. 1986;143(7):867–872.Google ScholarPubMed
33.Sernyak, MJ, Glazer, WM, Heninger, GR, et al. Naltrexone augmentation of neuroleptics in schizophrenia. J Clin Psychopharmacol. 1998;18(3):248–251.Google Scholar
34.Salloum, IM, Cornelius, JR, Chakravorthy, S. Utility of combined naltrexone valproate treatment in bipolar alcoholics: a randomized, open-label, pilot study. In: Diamond, I, ed. Abstracts of Papers, 26th Annual Scientific Meeting of the Research Society on Alcoholism, Ft. Lauderdale, FL, June 21–25, 2003. Baltimore, MD: Lippincott, Williams & Wilkins; 2003:843, 146A.Google Scholar
35.Petrakis, IL, Poling, J, Levinson, C, et al. Naltrexone and disulfiram in patients with alcohol dependence and comorbid post-traumatic stress disorder. Biol Psychiatry. 2006;60(7):777–783.Google Scholar